Reviews/GLP-1 Receptor Agonists/Tirzepatide 15 mg achieves 20% body weight loss
Metabolic · GLP1-MET-06 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
Across trials in people with obesity but not diabetes, the 15 mg dose of tirzepatide lowered body weight by roughly a fifth from where people started. Different trials landed at somewhat different points depending on how long people were treated and which population was studied, but they cluster near 20% [16][10][4][9][7]. In people who also had type 2 diabetes the drop was smaller [2][13], and in everyday clinical care outside a trial it was much smaller still [19]. The panel found the corpus genuinely carries the claim as worded, with the word 'approximately' doing real work because the exact figure moves between about 17.5% and 22.1%. The main caveats are that the strongest 72-week readouts combine the 10 mg and 15 mg doses, and that most of the evidence comes from one trial family funded by one company.
Multiple phase-3 randomised trials and their primary-data analyses in non-diabetic obesity place 15 mg weight loss near 20%: -22.1% in Japanese SURMOUNT-1 participants at 72 weeks [16], -19.7% at 176 weeks in obesity with prediabetes [10], and -17.5% at 52 weeks in SURMOUNT-CN [4]. SURMOUNT-1 overall decreased weight 'up to 20.9%' over 72 weeks [7], and SURMOUNT-5 reported -20.2% for the max-tolerated 10 or 15 mg dose [9]. In obesity with type 2 diabetes the effect is smaller, -14.7% at 15 mg [2] and -10.2% in a Japanese subpopulation [13]. A real-world EHR survey found tirzepatide associated with 'up to 9.6%' weight loss at a median exposure of about 4.6 months [19]. The contested point: The division is over precision and attribution, not direction: the two highest-relevance 72-week obesity readouts ([9] -20.2%, and the SURMOUNT-1 figure in [7]) report a pooled 10 or 15 mg max-tolerated dose rather than an isolated 15 mg arm, while clean isolated 15 mg figures come from a 52-week trial [4] and a 102-participant subpopulation [16]. Whether 'approximately 20%' is a clean 15 mg result or an inference from mixed-dose and short/long-duration readouts is where the evidence spreads.
All 20 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from GLP-1 Receptor Agonists, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The two highest-relevance 72-week non-diabetic obesity readouts ([9] -20.2%, SURMOUNT-1 in [7] 'up to 20.9%') report the max-tolerated 10/15 mg POOL, not an isolated 15 mg arm; clean isolated 15 mg obesity figures come from a 52-week trial (-17.5% [4]) and a small subpopulation analysis (-22.1%, n=102 [16]).
Most supporting papers are SURMOUNT-family, Eli Lilly-funded, and several are re-analyses of the single SURMOUNT-1 cohort ([7],[11],[12],[14],[15],[16],[17],[18]); evidential independence is limited, so convergence overstates confirmation.
Where it remains uncertain. The 72-week pivotal figures combine 10 and 15 mg [9][7], the effect falls to -14.7% in obesity with type 2 diabetes [2], and real-world weight loss is far lower at 'up to 9.6%' [19].
Aleatory
Real-world data show substantial variability in response regardless of exposure length, so the mean masks a wide spread [19].
Epistemic
The 72-week SURMOUNT-5 [9] and SURMOUNT-1 [7] figures combine 10 and 15 mg, so the isolated 15 mg magnitude at 72 weeks in the main cohort is not directly reported.
Inferential
Isolated 15 mg figures come from a Chinese trial [4] and a 102-participant Japanese subpopulation [16]; extending these to 'patients with obesity' broadly is an inference.
The load-bearing papers from a corpus of 20, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Shows 15 mg in obesity WITH T2D is attenuated to -14.7%, bounding the claim to the non-diabetic obesity scope.
“Least-squares mean change in bodyweight at week 72 with tirzepatide 10 mg and 15 mg was -12·8% (SE 0·6) and -14·7% (0·5), respectively”
Panel auditInternal validity: high · scope of inference: Adults with obesity and type 2 diabetes (BMI >=27, HbA1c 7-10%) over 72 weeks.Key limitations: diabetes population lowers weight loss · not obesity-only · HbA1c inclusion
Pivotal SURMOUNT-1 upper figure ~20.9% over 72 weeks in obesity.
“Tirzepatide treatment over 72 weeks decreased weight by up to 20.9%.”
Panel auditInternal validity: medium · scope of inference: Adults with obesity or overweight; weight change reported only as a top-line maximum.Key limitations: post-hoc · 'up to' phrasing not dose-attributed · uric acid focus
Non-diabetic obesity, max-tolerated 10/15 mg: -20.2% at 72 weeks.
“The least-squares mean percent change in weight at week 72 was -20.2% (95% confidence interval [CI], -21.4 to -19.1) with tirzepatide”
Panel auditInternal validity: high · scope of inference: Adults with obesity but without type 2 diabetes over 72 weeks, pooled 10/15 mg.Key limitations: pooled MTD dose · open-label · 15 mg not isolated
Isolated 15 mg -17.5% at 52 weeks (shorter duration) — lower bound of the ~20% cluster.
“The mean change in body weight at week 52 was -13.6% (95% CI, -15.8% to -11.4%) with tirzepatide 10 mg, -17.5% (95% CI, -19.7% to -15.3%) with tirzepatide 15 mg, and -2.3% with placebo”
Panel auditInternal validity: high · scope of inference: Chinese adults with obesity or overweight (BMI >=28 or >=24) excluding diabetes, 52 weeks.Key limitations: lower baseline weight (91.8 kg) population · borderline below 20% · 52-week duration
4 of 20 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Convergent isolated-dose and pivotal-trial evidence supports the hedged ~20% figure for 15 mg in obesity, with points deducted for dose-pooling in the 72-week pivotals, SURMOUNT-family dependence, and real-world attenuation.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Isolated 15 mg figure at 72 weeks. The pivotal 72-week readouts pool 10 and 15 mg [9][7], so the headline duration lacks a clean isolated-dose number for the main cohort. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Report or analyse the isolated 15 mg arm percent weight change at 72 weeks in the full SURMOUNT-1 cohort.
Open question: What is the isolated 15 mg mean percent weight loss at 72 weeks in the full non-diabetic obesity cohort? Why it is still open: The 72-week pivotal figures are reported as a 10 or 15 mg pool [9][7], not an isolated 15 mg arm.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19